AlloNK

Artiva Biotherapeutics Advances AlloNK Toward Phase 3 in RA

SAN DIEGO, California — September 8, 2026 Artiva Biotherapeutics, Inc. announced planned clinical data disclosures and development milestones for...

By cGxPwire Editor
September 9, 2026

.Clinical

Artiva Biotherapeutics Showcases AlloNK Data at EULAR 2026

SAN DIEGO, California, May 19, 2026 Artiva Biotherapeutics announced multiple data presentations at the upcoming EULAR 2026 Congress highlighting...

By cGxPwire Editor
May 20, 2026

Bio-Pharma

Artiva Highlights Durable AlloNK Outcomes at 2026 Tandem

San Diego, California, January 21, 2026 — Artiva Biotherapeutics, a clinical-stage biopharmaceutical company focused on allogeneic natural killer (AlloNK)...

By cGxPwire Editor
January 22, 2026

We work Hard to get you posted with latest updates

Unwrap our new Directory

Artiva Biotherapeutics Advances AlloNK Toward Phase 3 in RA

Artiva Biotherapeutics Showcases AlloNK Data at EULAR 2026

Artiva Highlights Durable AlloNK Outcomes at 2026 Tandem